Kindeva Drug Delivery has announced the opening of a 32,000 sq ft laboratory facility in Woodbury, MN, USA that will be home to the company’s new analytical services business unit. According to the announcement, the analytical services offered include medical device, container closure, and extractables and leachables testing. The company said that extractables and leachables and elemental impurities testing services will be led by longtime Kindeva / 3MDDS employee Dan Dohmeier; and the container closure integrity and medical device services will be led by Michael Dominguez, who joins the company from testing labs DDL, Inc.
Kindeva Global Chief Commercial Officer Dave Stevens commented, “Offering considerable analytical testing capabilities on a stand-alone basis to the wider pharmaceutical and device industry is an important step for Kindeva’s growing role as a global contract analytical, development, and manufacturing organization. 2024 is an exciting year for bringing many areas of needed industry solutions to fruition with the opening of a brand new world-class, state-of-the-art sterile injectable facility in Bridgeton, Missouri . . . as well as the operationalization of our first 152a green propellant-capable GMP capacity in Loughborough, UK. Expanding the analytical suite of capabilities and capacity reflects our ambition to be a true full-service partner and market leader in the CRO/CDMO industry and further accelerate the safety and efficacy objectives of innovators.”
Read the Kindeva Drug Delivery press release.
